Note: Live price is not available for this stock. Showing closing price. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
LUPIN Stock Analysis
Views
Red Flags
Positive
Stock is reasonably valued and PE TTM is at a discount to industry median
Strong price momentum
Analysts have been raising forward EPS estimates
High and improving ROE
High and improving operating margin
Moderate revenue growth and above median growth of industry
Strong EPS growth and above median growth of industry
Low Debt to Equity, not much change from last year
Consistently pays dividend
Company is net cash
Negative
Low dividend yield
Neutral
Company's earnings are of moderate quality
No red flags found!
No significant red flags found in the stock.
Snapshot
See detailed analysis
LUPIN Shareholding Pattern
An overview of who owns the company. Click on chart icon to view historical movement.
LUPIN Bulk, Block & Insider Trades
LUPIN Dividends, Splits & Bonus
Dividend Events
Capital Change Events
Bonus
Stock split
Others
Bonus(1 new shares for 1 existing shares)Bonus issue of 40152494 securities Ex-date: 11th Aug 2006 Announced on: 26th Jul 2006
Stock split(1 : 5)BOD 05 May 2010. Nominal valued changes from INR 10 to INR 2. Ex-date: 27th Aug 2010 Announced on: 5th May 2010
Non-renounceable scrip issue in different stockMerger of <LUPL.BO> into <LUPN.BO>. Swap ratio: 12 shares of <LUPN.BO> for every 1 share of <LUPL.BO>. The merged entity will be called Lupin Ltd. The share capital of <LUPN.BO> is being re-organised whereby the face value of RS 10 would reduce to RS 1 per share and the balance of RS 9 would be tran... Read More Ex-date: 16th Jul 2001 Announced on: 2nd Feb 2001
Company Profile
Lupin Limited is a global pharmaceutical company, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates in India and the United... Read More
Key personnel
Mrs. Manju Deshbandhu GuptaD
Non-Executive Chairman of the Board
Ms. Vinita D. GuptaD
Chief Executive Officer, Executive Director
Mr. Ramesh SwaminathanD
Executive Director, Global Chief Financial Officer, Chief Risk Officer and Head of API Plus SBU
Dr. Fabrice Egros
President - Corporate Development
Mr. Spiro Gavaris
President - US Generics
Mr. Claus Jepsen
President - Global Specialty
Dr. Cyrus Karkaria
President - Biotech Business
Mr. Yashwant (Yash) Mahadik
President - Global Human Resources
View all
Incorporated on
Last Annual
Last Interim
No. of Employees
IPO date
Free Float
Website
Phone no.
Address
Frequently asked questions
What is the current share price of Lupin Ltd.?
The current share price of Lupin Ltd. is ₹ 2,181.82 as of 09 Jan 2026.
What is the PE ratio of Lupin Ltd.?
The Price-to-Earnings (PE) ratio of Lupin Ltd. is 23.01 as of the latest financial data.
What is the ROE and ROCE of Lupin Ltd.?
Lupin Ltd. has a Return on Equity (ROE) of 24.56% and a Return on Capital Employed (ROCE) of 22.86% as per the latest financial reports.
What is the market cap of Lupin Ltd.?
The market capitalization of Lupin Ltd. stands at ₹ 99,665.30 Cr.
What is the dividend yield of Lupin Ltd.?
The dividend yield of Lupin Ltd. is 0.55% based on the current market price.
What is the RSI of Lupin Ltd.?
The Relative Strength Index (RSI) of Lupin Ltd. is 63.55.
What is the FII and DII holding in Lupin Ltd.?
Foreign Institutional Investors (FII) hold 20.50% and Domestic Institutional Investors (DII) hold 25.05% of Lupin Ltd. shares.
What sector does Lupin Ltd. belong to?
Lupin Ltd. operates in the Healthcare sector.
What is the beta of Lupin Ltd. stock?
The beta of Lupin Ltd. stock is 0.99, indicating its volatility relative to the broader market.
